by B2i | Nov 15, 2022 | Press Releases
ROCKVILLE, Md., Nov. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a...
by B2i | Nov 3, 2022 | Press Releases
ROCKVILLE, Md., Nov. 3, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its...
by B2i | Nov 2, 2022 | Press Releases
ROCKVILLE, Md., Nov. 1, 2022 –Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
by B2i | Sep 20, 2022 | Press Releases
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md., Sept. 20, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of...
by B2i | Sep 15, 2022 | Press Releases
Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md., Sept. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the...
by B2i | Sep 6, 2022 | Press Releases
ROCKVILLE, Md., Sept. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
